|
View this as a webpage
On Aug. 22, the U.S. Food and Drug Administration (FDA) took action approving and authorizing for emergency use of updated mRNA COVID-19 vaccines, FDA: FDA Approves and Authorizes Updated mRNA COVID-19 Vaccines to Better Protect Against Currently Circulating Variants.
As part of FDA’s actions, the 2023–2024 Moderna and Pfizer-BioNTech COVID-19 vaccines are no longer authorized for use in the United States and should not be administered.
Providers should:
- Remove all 2023-2024 COVID-19 vaccines from storage units immediately, even if they are not expired.
- Report all unused 2023-2024 COVID-19 vaccines as nonviable in the Minnesota Immunization Information Connection (MIIC).
Visit our user guide on reporting nonviable vaccine in MIIC for more detail, Reporting Nonviable MDH Vaccine to MIIC (PDF) (www.health.state.mn.us/people/immunize/miic/managevax/nonviable.pdf).
We are still awaiting information from CDC on the new 2024-2025 products. We hope to share more detail, including how to order, in the coming days.
Bridge program update
Aug. 22 marked the end of the Bridge Access Program as the U.S. FDA authorized the updated COVID-19 monovalent vaccine (2024-2025 formula). Additionally, we recently received further guidance from the CDC that the reimbursement of the administration fees for the COVID-19 doses must also end. Providers may invoice for all doses administered of the bivalent vaccine (2023-2024 formula) through August 22, 2024. If your clinic participates in the DLE model, the Minnesota Department of Health will only include doses administered between those date ranges. Thank you again for all your work and partnership in the Bridge Access Program.
Contact the UUAV program staff at health.uuadultvax@state.mn.us or 651-201-5522.
|
